Ann Lab Med.  2014 Sep;34(5):399-401. 10.3343/alm.2014.34.5.399.

Rapid Sequential Gain of ABL1 Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia

• Chung Y
• Eom HS
• Lee H
• Park S
• Shim H
• Cho EH
• Kong SY

• KMID: 1791958
• DOI: http://doi.org/10.3343/alm.2014.34.5.399

Abstract

No abstract available.

MeSH Terms

Base Sequence
Benzamides/therapeutic use
Bone Marrow/pathology
Female
Fusion Proteins, bcr-abl/*genetics
Humans
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/*genetics
Middle Aged
Philadelphia Chromosome
Piperazines/therapeutic use
Protein Kinase Inhibitors/therapeutic use
Pyrimidines/therapeutic use
Sequence Analysis, DNA
Thiazoles/therapeutic use
Translocation, Genetic
Benzamides
Fusion Proteins, bcr-abl
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Thiazoles

Figure

• 

  Fig. 1 The mutational analysis of ABL1 kinase domain with conventional direct sequencing at the time of diagnosis (top row), after development of imatinib resistance (middle row), and after development of dasatinib resistance (bottom row). (A) E255K (c.763G>A) was detected after development of imatinib resistance. (B) T315I (c.944C>T) was first detected after switchover to dasatinib resistance.

Reference

1. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23:1054–1061. PMID: 19282833.

2. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002; 359:487–491. PMID: 11853795.

3. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16:2190–2196.

4. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007; 92:401–404. PMID: 17339191.

5. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009; 27:4204–4210.

6. Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009; 114:4944–4953.

7. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27:6041–6051.

8. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984; 63:789–799. PMID: 6584184.

9. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, et al. German chronic myeloid leukaemia (CML)-Study Group. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol. 1997; 97:76–85.

10. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293:876–880.

11. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011; 118:1208–1215.

12. Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Müller MC, et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica. 2009; 94:1227–1235.

13. Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol. 2011; 29:4250–4259.

14. Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 2012; 119:2234–2238.